Aura Biosciences (AURA) Cash & Current Investments (2020 - 2026)

Aura Biosciences (AURA) has 7 years of Cash & Current Investments data on file, last reported at $84.8 million in Q1 2026.

• Quarterly Cash & Current Investments rose 121.82% year-over-year to $84.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $84.8 million (up 121.82% YoY) and the FY2025 annual result came in at $59.5 million, up 87.79% from the prior year.
• Cash & Current Investments climbed to $84.8 million in Q1 2026, from $59.5 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $107.4 million in Q2 2025 to a low of $20000.0 in Q4 2022.
• A 5-year average of $38.5 million and a median of $38.2 million in 2025 frame the typical range for Cash & Current Investments.
• The widest YoY moves for Cash & Current Investments: up 305450.0% in 2022, down 99.99% in 2022.
• Tracing AURA's Cash & Current Investments over 5 years: stood at $20000.0 in 2022, then jumped by 205215.0% to $41.1 million in 2023, then retreated by 22.82% to $31.7 million in 2024, then jumped by 87.79% to $59.5 million in 2025, then jumped by 42.47% to $84.8 million in 2026.
• The last three Cash & Current Investments figures came in at $84.8 million (Q1 2026), $59.5 million (Q4 2025), and $47.6 million (Q3 2025), per Business Quant data.